Entera Bio Ltd
NASDAQ:ENTX 4:00:00 PM EDT
Products, Earnings Announcements
Entera Bio Reports FDA Approval Of IND Application For EB613
Published: 12/10/2020 14:57 GMT
Entera Bio Ltd (ENTX) - Entera Bio Announces FDA Approval of Ind Application for Eb613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis.
Entera Bio - Look Forward to Reporting Final Biomarker Data in Q1 of 2021 for Eb613.
Entera Bio Ltd - Look Forward to Reporting Final Bone Mineral Density Data From Eb613 Trial in Q2 of 2021.
Entera Bio - Look Forward to Reporting Final Biomarker Data in Q1 of 2021 for Eb613.
Entera Bio Ltd - Look Forward to Reporting Final Bone Mineral Density Data From Eb613 Trial in Q2 of 2021.
Revenue is expected to be $0.1 Million
Adjusted EPS is expected to be -$0.12
Next Quarter Revenue Guidance is expected to be $0.1 Million
Next Quarter EPS Guidance is expected to be -$0.14
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.12
Next Quarter Revenue Guidance is expected to be $0.1 Million
Next Quarter EPS Guidance is expected to be -$0.14
More details on our Analysts Page.